It is not entirely surprising to come across a paper suggesting that male carriers of the BRCA1/2 genes are at risk for worse post-treatment outcomes than non-carriers of these genes after standard forms of first-line treatment for prostate cancer. Castro et al. looked at data from a cohort of > 1,300 men who received definitive […]![]()
